Seegene, Inc. 096530
KRX · South Korea · Health Technology
KRW 37,300.00+1,850.00 (+5.22%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The Association for Diagnostics & Laboratory Medicine (ADLM) is pleased to announce the recipients of its 2026 Top Corporate Supporter Award, a distinction given to companies and organizations that generously support the association through advertising, sponsorships, and exhibits. These significant contributions make it possible for ADLM to further its mission of better health for all through laboratory medicine.
Seegene Inc., a global molecular diagnostics company, announced a comprehensive syndromic PCR-based testing approach for reproductive tract infections (RTIs) through the simultaneous detection of sexually transmitted infections (STIs) and human papillomavirus (HPV).
Seegene, Inc. ("Seegene"), a global leader in molecular diagnostics, announced today that its U.S. subsidiary, Seegene USA, Inc. ("Seegene USA"), has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Allplex™ HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR assay designed to simultaneously detect multiple viral pathogens associated with clinically overlapping lesion presentations.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.